Dr. Argilés on BRAF-Mutations in Colorectal Cancer

Guillem Argiles, MD
Published: Friday, Jul 10, 2015




Guillem Argilés, MD, department of Medical Oncology, Vall d’Hebron University Hospital, discusses the benefits of molecular subtyping in colorectal cancer.

Identifying new subtypes in colorectal cancer has made a significant impact on treatment options for colorectal cancer, Argilés says.

By identifying and targeting BRAF-mutations, patients with a previously poor prognosis are experiencing improved survival outcomes and response rates.

Additional subtyping and targeted therapies for those molecular subtypes is key to combating colorectal cancer, says Argilés.
 



Guillem Argilés, MD, department of Medical Oncology, Vall d’Hebron University Hospital, discusses the benefits of molecular subtyping in colorectal cancer.

Identifying new subtypes in colorectal cancer has made a significant impact on treatment options for colorectal cancer, Argilés says.

By identifying and targeting BRAF-mutations, patients with a previously poor prognosis are experiencing improved survival outcomes and response rates.

Additional subtyping and targeted therapies for those molecular subtypes is key to combating colorectal cancer, says Argilés.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x